Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of Tepotinib in Combination With Paclitaxel in Patients With MET Amplified or MET Exon 14 Alterated Advanced Gastric and Gastroesophageal Junction Carcinoma

NCT05439993 is registered in ClinicalTrials.gov with Hallym University Medical Center as lead sponsor.

NCT NCT05439993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05439993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of Tepotinib in Combination With Paclitaxel in Patients With MET Amplified or MET Exon 14 Alterated Advanced Gastric and Gastroesophageal Junction Carcinoma
Lead sponsor
Hallym University Medical Center
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 1, 2022
Completion date
June 30, 2026
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastroesophageal-junction cancer